Annals of Oncology

356P Prognostic value of the residual cancer burden after neoadjuvant chemotherapy for invasive lobular breast cancer: An international pooled cohort study.

Annals of Oncology

S. Gottipati, H.M. Earl, C. Yau, D.A. Cameron, J. Abraham, L. Hayward, F. Reyal, M. Osdoit, G.S. Sonke, J. Wesseling, J. Boughey, M.P. Goetz, A. DeMichele, L. Pusztai, P. Sharma, M. Martin Jimenez, S. Lopez-Tarruella Cobo, M. Del Monte-Millan, F. Symmans, R. Mukhtar

1229P A multicenter phase II study of sotigalimab (CD40 agonist) in combination with neoadjuvant chemoradiation for resectable esophageal and gastroesophageal junction (GEJ) cancers.

Annals of Oncology

A.H. Ko, M. Noel, J. Chao, D. Sohal, M. Crow, P.E. Oberstein, A. Scott, A. McRee, C. Rocha Lima, L. Fong, B. Keenan, E. Filbert, F.J. Hsu, V. Shankaran

512O Interim results from a phase II study of the ATR inhibitor ceralasertib in ARID1A-deficient and ARID1A-intact advanced solid tumor malignancies.

Annals of Oncology

R. Aggarwal, S. Umetsu, M. Dhawan, J. Grabowsky, J. Carnevale, M. Howell, L. Wilch, J. Chapman, E. Alvarez, S. Calabrese, S. Smith, N. Shah, E. Dean, P. Munster, E. Collisson

O4.2 Development of novel small molecule MerTK and Flt3 tyrosine kinase inhibitors for treatment of acute leukemia.

Annals of Oncology

D. Graham, D. DeRyckere, K. Minson, C. Smith, A. Hill, M. Huey, E. Lasater, X. Wang, N. Shah, S. Frye, H. Shelton Earp